Actualités

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 5.1% in the afternoon session after the stock's positive momentum was extended as the company, along with partner Merck, presented positive long-term data for its personalized mRNA-based cancer vaccine.

Moderna (MRNA) was one of the big beneficiaries of the Covid pandemic, producing tens of billions of dollars in vaccine sales and becoming one of the most carefully watched businesses in biotechnology. Since then, the task has been to prove that the accomplishment was not a fluke. As Covid-related ...

Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Although Moderna has outperformed the broader health care sector over the last 12 months, analysts maintain a cautious stance on the stock’s future outlook.

Moderna Inc. (NASDAQ:MRNA) is one of the 10 Stocks With Remarkable Resilience. Moderna snapped a four-day losing streak on Wednesday, jumping 7.49 percent to finish at $49.06 apiece, as investors positioned portfolios ahead of its participation in a conference next week. In a notice to investors, Moderna Inc. (NASDAQ:MRNA) said that it is set to […]

It is finally bouncing back after several challenging years.

Moderna (NasdaqGS:MRNA) has expanded its collaboration with CEPI to accelerate development of an mRNA vaccine targeting Bundibugyo ebolavirus. The partnership focuses on responding to an ongoing Ebola outbreak in Central Africa, where no approved vaccines currently exist for this strain. CEPI funding is intended to support rapid research and early stage development using Moderna's mRNA platform for epidemic preparedness. For readers tracking Moderna beyond its Covid-19 work, this move fits...

Moderna gains up to $50M from CEPI to advance a Bundibugyo ebolavirus vaccine as the partnership expands amid an ongoing Ebola outbreak.

We recently compiled a list of the 8 Best Immunology Stocks to Buy According to Hedge Funds. Moderna, Inc. (NASDAQ:MRNA) is among the best immunology stocks to invest in. TheFly reported earlier this month, on May 4, that UBS increased its price objective on MRNA to $45 from $36 while continuing to hold a Neutral stance […]

VRTX stock falls 7.9% in three months as Journavx and Casgevy sales missed expectations, but CF growth, Alyftrek momentum and renal pipeline progress stand out.

Earnings season is winding down, but we still have a couple of big name companies reporting. This week we have Broadcom, Crowdstrike, Palo Alto Networks, Medtronic and Ciena Corp all reporting.

Moderna (NASDAQ:MRNA) announced on Monday a new collaboration with an international health organization aimed at accelerating the development of a vaccine targeting Bundibugyo ebolavirus (BDBV), the strain responsible for the ongoing Ebola outbreak in eastern Democratic Republic of Congo. The partnership comes as global health agencies intensify efforts to identify effective treatments and preventive measures for the outbreak, which has resulted in more than 900 suspected infections and over 220

Anterix enables secure wireless communications for utilities and critical infrastructure through its nationwide 900 MHz spectrum portfolio.

Investing.com -- J.P. Morgan has reinstated coverage on 14 large-cap biotechnology companies, arguing the sector is entering a major inflection point as pipeline successes increasingly translate into profitable and diversified commercial businesses.

BioNTech’s future rests entirely on the success of its pipeline, now that its pandemic-era glory days are firmly in the rearview mirror. Wall Street is betting the company’s next act in oncology will be worth the wait. UBS analyst David Dai moved off the sidelines Wednesday as he upgraded BioNTech stock to Buy from Neutral with a $135 price target, up from $117.

The Japanese pharma is aiming for $1.3 billion in yearly savings between now and 2030. Elsewhere, Datroway gained a new clearance in breast cancer and the FDA approved a drug for hepatitis D.

In May 2026, Roivant Sciences reported fourth-quarter 2026 results showing sales of US$2.52 million, a swing to quarterly net income of US$302.99 million, and full-year 2026 sales of US$8.26 million alongside a wider annual net loss of US$299.77 million. The earnings were heavily influenced by a US$770.2 million litigation settlement gain linked to Genevant’s US$2.25 billion global patent settlement with Moderna, highlighting how non-operating items and asset monetization can meaningfully...

Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses risk dilution, mounting debt, or even bankruptcy.

On May 6, 2026, Moderna’s board amended its bylaws to require Securities Act of 1933 lawsuits be filed exclusively in US federal district courts, aligning with recent Delaware law changes, while the FDA set a June 18 advisory panel review for the company’s mRNA-based seasonal flu vaccine after an earlier filing setback. Together with ongoing insider share sales under a preset trading plan and fresh real-world data on its pediatric COVID-19 vaccine effectiveness, these developments sharpen...

Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth. This has capped returns as the industry’s six-month gain of 7.8% has lagged the S&P 500’s 13.2% climb.

The Food and Drug Administration is eyeing a meeting on June 18 to discuss mRNA-1010.

Moderna (NASDAQ:MRNA) is back in the headlines after ripping 63.17% higher year to date on a surprise Q1 revenue triple and renewed pipeline excitement. But the underlying story deserves a closer look. The Moderna Story Has Not Changed Strip away the bounce and the fundamentals tell the same story long-term investors have heard for three ... Forget Moderna: This Biotech Juggernaut Is a Way Better Buy Right Now

Investing.com -- JPMorgan has reinstated ratings and price targets on 14 large-cap biotechnology companies, describing the sector as being at a critical “inflection point” as pipeline successes increasingly translate into profitable commercial franchises.

Roivant Sciences Ltd (ROIV) strengthens its financial position with a $2.25 billion Moderna settlement and prepares for key drug launches amidst mixed study results.

Roivant Sciences (NASDAQ:ROIV) executives used the company’s fourth-quarter earnings call to highlight new open-label data for IMVT-1402 in difficult-to-treat rheumatoid arthritis, upcoming pulmonary hypertension data for mosliciguat and continued preparation for a potential brepocitinib launch in d

On Wednesday, Roivant Sciences Ltd. (NASDAQ:ROIV) posted fourth-quarter adjusted earnings per share of $0.

The Food and Drug Administration is rudderless. Its commissioner, Marty Makary, is gone. The rise of the Make America Healthy Again movement, with its vaccine skepticism and adversarial stance toward drugmakers, has hung over biotech since Robert F. Kennedy Jr. took over at the Department of Health and Human Services.

Roivant Sciences has seen only a marginal shift in its modeled fair value, from US$35.67 to US$35.71, keeping the headline price target effectively stable. That small move reflects a tug of war in analyst commentary, with optimism around the US$2.25b Genevant and Arbutus settlement and key brepocitinib milestones set against questions about how much of this is already in the stock. Read on to see how to track these shifting views and what to watch as the Roivant story continues to...

Wall Street futures were heading deeper into the red ahead of Tuesday's opening bell, as investors remained unconvinced about reports on the latest US-Iran diplomacy efforts. Futures tracking the Nasdaq 100 pointed to an 0.8% drop, while S&P 500 futures were down 0.4% and those for the...

Moderna (MRNA) is back in focus after Phase 3 data showed its mRNA flu vaccine outperformed standard shots in older adults, while separate hantavirus research tied to a cruise ship outbreak added further attention. See our latest analysis for Moderna. The latest flu and hantavirus updates come after a powerful run, with the stock showing a 58.91% year-to-date share price return and a very large 1-year total shareholder return. However, longer-term total shareholder returns over 3 and 5 years...